Bristol Myers Squibb stock gains focus before October 29 results

{
  "signal_id": "623a7f0d-813c-ac4c-2953-503ccc8a52ab",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-09-19T09:53:49+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/bristol-myers-squibb-stock-gains-focus-before-october-29-results/70130641",
    "title": "Bristol Myers Squibb stock gains focus before October 29 results - AD HOC NEWS",
    "excerpt": "Bristol Myers Squibb Company (ISIN US1101221083) ended at USD 62.84 on the New York Stock Exchange on September 17, 2026, leaving the stock about 8.4 percent below its 52-week high of USD 68.64 and valued at about USD 129.46 billion. According to Business Wire on September 18, 2026, Bristol Myers Squibb will report results for the third quarter of 2026 on October 29, 2026, with the call set for 8:00 a.m. ET. Reuters said on September 18, 2026, that BMY this year signed a partnership with Jiangsu Hengrui Pharma worth up to USD 15.2 billion. For investors, that date matters because the quarter will be measured against a 2025 base in which revenue reached about USD 48.2 billion and net income was nearly USD 7.1 billion, according to Mitrade on September 18, 2026. The same report put the 2025 net margin at about 14.6 percent and the debt-to-equity ratio at roughly 2.6x. That valuation backdrop is part of the current debate. Mitrade said Bristol Myers Squibb traded at a forward P/E of 9.2x versus AbbVie at 18.5x, while Zacks said on September 18, 2026, that the 2026 EPS estimate for BMY had risen to USD 6.91 from USD 6.34 in the past 60 days and the 2027 estimate to USD 6.46 from USD 6.12. Reuters also reported on September 18, 2026, that US authorities are weighing rules that could preserve most licensing deals with China, a point that matters for Bristol Myers Squibb after its...",
    "summary": "Bristol Myers Squibb signed a partnership with Jiangsu Hengrui Pharma this year, potentially worth up to USD 15.2 billion.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2404994_1920_1080.webp",
    "confidence": 0.9,
    "published_at": "2026-09-19T09:53:49Z",
    "article_sentence": "Reuters said on September 18, 2026, that BMY this year signed a partnership with Jiangsu Hengrui Pharma worth up to USD 15.2 billion.",
    "amount_normalized": 15200000000,
    "related_company_name": "Jiangsu Hengrui Pharma",
    "related_company_domain": "hrs.com.cn"
  }
}

curl https://signals.autobound.ai/v1/signals/623a7f0d-813c-ac4c-2953-503ccc8a52ab \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bms.com","limit":20}'